Janux Therapeutics Inc
JANXHealthcare|Biotechnology|USA
$16.41
-0.35 (-2.09%)
DCF (FCF)
$5.59
Tangible Book
$15.47
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05783622 Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Non-Small Cell Lung Cancer, Renal Cell Carcinoma | P1 | Active | 130 | Open-label | JANX008 |
| NCT07545811 Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | P1 | Recruiting | 43 | Open-label | JANX014 |
| NCT05519449 Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Prostate Cancer, Metastatic Castration-resistant Prostate Cancer | P1 | Recruiting | 272 | Open-label | JANX007, Darolutamide |
| NCT07291323 Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. | Autoimmune | Early P1 | Recruiting | 60 | Open-label | JANX011 |